Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/513—Organic macromolecular compounds; Dendrimers
  • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/28—Insulins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39591—Stabilisation, fragmentation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/513—Organic macromolecular compounds; Dendrimers
  • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
  • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
  • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K16/241—Tumor Necrosis Factors
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K16/244—Interleukins [IL]
  • C07K16/248—IL-6
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Definitions

• Proteins and peptides have been used for many years to treat diseases such as diabetes, heart disease, and cancer, and are used in vaccines. In most cases, the oral delivery of these agents fails due to the acidic conditions in the stomach. In addition, in vitro experiments have shown that many proteins and peptides are rapidly inactivated or destroyed in the presence of enzymes naturally occurring in the digestive tract. Finally, therapeutic proteins or peptides can be chemically or physically unstable in the presence of an excess of hydrogen ions or hydroxyl ions. Therefore, therapeutic proteins or peptides are generally delivered to patients parenterally.
• Diabetes is characterized by chronic high blood glucose levels. As of 2014, an estimated 387 million people worldwide had diabetes, with especially high numbers in underdeveloped and developing countries. It is estimated that there will be 592 million diabetes patients by 2035. Therefore, diabetes is a critical global problem.
• Insulin a peptide hormone
• Insulin is used to treat some forms of diabetes. It generally is delivered in liquid injection form because of its short half-life and degradation in the gastrointestinal tract. Because insulin must be administered frequently in an injectable form, patients, especially children, find it inconvenient. Therefore, there is great demand for the development of a more convenient non -injectable form of insulin, such as an oral dosage form.
• Solvent evaporation is a common method to prepare solid solutions or dispersions by dissolving drug and carrier in a solvent and then evaporating the solvent. The resultant solid mass is ground and sieved. However, it is difficult with this method to scale up and to achieve physical and chemical stability.
• Nanoprecipitates are prepared by transferring a solution of drug and polymer in a water-mi scible solvent into an aqueous solution containing a stabilizer. Co- precipitates are formed instantaneously by rapid solvent diffusion.
• a solution containing drug and polymer in a water immiscible solvent e.g., dichloromethane or chloroform
• a water immiscible solvent e.g., dichloromethane or chloroform
• the subsequent evaporation of the solvent from the oil/water emulsion results in the formation of microparticles and/or nanoparticles.
• the emulsification- diffusion method is similar to the emulsification-evaporation method, but uses a partially water- soluble solvent (e.g., benzyl alcohol). A large amount of water is needed to induce the diffusion of the solvent from the oil/water emulsion to form particles.
• an organic solution of polymer and drug is emulsified into an aqueous phase containing an electrolyte (e.g., MgCl 2 ) and a stabilizer (e.g., polyvinyl alcohol).
• an electrolyte e.g., MgCl 2
• a stabilizer e.g., polyvinyl alcohol
• Sufficient water is subsequently added to the emulsion to induce the diffusion of the organic solvent into the water, leading to polymer precipitation and formation of microparticles and/or nanoparticles.
• a complicated purification stage is necessary to eliminate the high amounts of emulsifying agent and electrolyte.
• PCT application WO 2010/113177 discloses an oral insulin pH-sensitive delivery agent containing insulin and a methacrylic acid/methylmethacrylate copolymer (EUDRAGIT L100).
• the agent is prepared by a double emulsion technique using liquid paraffin, which is unstable.
• U.S. published patent application US 2010/021549 describes a core-shell particle containing insulin and pH-sensitive polymers, such as hydroxypropyl methylcellulose phthalate (HPMCP) and hydroxypropyl methylcellulose acetate succinate (HPMCAS).
• HPMCP hydroxypropyl methylcellulose phthalate
• HPMCAS hydroxypropyl methylcellulose acetate succinate
• the release of insulin from the particle is slow in an acidic medium but fast in a neutral medium.
• the particle is prepared by a fluidized bed spraying technique, resulting in particles having a diameter of about 2 mm.
• the mixture was stirred at 500 RPM for the precipitation of drug and polymer, and the resulting opalescent dispersion was filtered through a 20 ⁇ pore filter.
• the insulin loading efficacy was 18-30%.
• the particles ranged in size from about 135 nm to about 200 nm.
• Particle size is a crucial factor to determine the absorption, distribution, and in vivo performance of polymer-based formulations for oral delivery.
• nanoparticles have a higher cellular uptake efficiency than microparticles.
• Nanoparticles with a particle size ⁇ 100 nm are efficiently taken up in Peyer's patches, and then absorbed into the systemic circulation (Woitiski CB, et al.. Strategies Toward the Improved Oral Delivery of Insulin Nanoparticles via Gastrointestinal Uptake and Translocation, BioDrugs 2008;22:223).
• the present invention provides compositions containing nanoparticles for enteric delivery of therapy agents, and methods for making the nanoparticles.
• One aspect of the invention is a composition for use in an oral formulation of a therapeutic agent.
• the composition includes a plurality of nanoparticles having a mean particle size of 50 nm or less, thereby offering high bioavailability.
• the composition includes a pH- sensitive polymer and a therapeutic agent having a molecular weight of about 10000 Daltons or less.
• the therapeutic agent has a molecular weight between about 1000 and about 10000 Daltons.
• the therapeutic agent is associated with, adhered to, or embedded within the nanoparticles.
• the nanoparticles consist essentially of the pH-sensitive polymer and the therapeutic agent.
• the composition further includes a component selected from the group consisting of a surfactant, a lipid, a mucoadhesive polymer, and combinations thereof.
• the composition dissociates at a pH greater than about 5.0. In certain preferred embodiments, less than 5% of the therapeutic agent is released from the nanoparticles in 2 hours in an aqueous solution at a pH of less than about 2.0.
• the nanoparticles described above have a mean particle size from about 10 nm to about 30 nm.
• the therapeutic agent is a peptide, protein, nucleic acid, small molecule drug, or a combination thereof.
• the therapeutic agent is insulin.
• the pH-sensitive polymer includes, or is composed of, anionic polymers containing carboxyl groups.
• the pH- sensitive polymer is an anionic co-polymer of methylmethacrylic acid and methacrylic acid, such as poly(methacrylic acid-co-methyl methacrylate) 1 : 1, poly(methacylic acid-co-methyl methacrylate) 1 :2.
• the pH-sensitive polymer is an anionic polymer of hydroxypropyl methylcellulose, such as hydroxypropyl methylcellulose phthalate, or hydroxypropyl methylcellulose acetate succinate.
• compositions for an oral formulation of a therapeutic agent including a plurality of nanoparticles having a mean particle size of 100 nm or less.
• the composition includes a pH-sensitive polymer and a therapeutic agent having a molecular weight of greater than about 10000 Daltons.
• the therapeutic agent has a molecular weight from greater than about 10000 Daltons to about 400000 Daltons.
• the composition consists essentially of the pH-sensitive polymer and the therapeutic agent.
• the composition further includes a component selected from the group consisting of a surfactant, a lipid, a mucoadhesive polymer, and combinations thereof.
• the composition dissociates at a pH greater than about 5.0.
• the therapeutic agent is a peptide, a protein, a nucleic acid, an antibody, a vector, a virus-like particle, a vaccine, or a combination thereof.
• the therapeutic agent is an antibody.
• the antibody is selected from the group consisting of anti-EGFR, anti-Her2, anti-RSV, anti-interleukin, and anti-TNF.
• the antibody is selected from the group consisting of cetuximab, trastuzumab, palivizumab, tocilizumab, and adalimumab.
• the pH-sensitive polymer is an anionic co-polymer of methylmethacrylic acid and methacrylic acid, such as poly(methacrylic acid-co-methyl methacrylate) 1 : 1, poly(methacylic acid-co-methyl methacrylate) 1 :2.
• the pH-sensitive polymer is an anionic polymer of hydroxypropyl methylcellulose, such as hydroxypropyl methylcellulose phthalate, or hydroxypropyl methylcellulose acetate succinate.
• Yet another aspect of the invention is a method of preparing an orally administrable formulation of a therapeutic agent.
• the method includes the steps of: (a) providing an aqueous solution including the therapeutic agent and a pH-sensitive polymer, the solution having a pH of greater than about 5.5 and containing nanoparticles; and (b) lowering the pH of the solution to less than about 4.0, whereby the therapeutic agent and the polymer co-precipitate and the polymer entraps the therapeutic agent, and wherein the polymer is capable of dissociation at a pH greater than about 5.0, releasing the therapeutic agent.
• step (a) includes providing an aqueous solution including the therapeutic agent and pH-sensitive polymer at a pH below 5.0 and then raising the pH to above 5.5 by the addition of a buffer at pH 5.5-8 or a solution containing a surfactant, such as taurocholate or another bile acid, a lipid, a buffer, and optionally one or more stabilizers for maintaining the activity of the therapeutic agent.
• a surfactant such as taurocholate or another bile acid
• a lipid e.g., a lipid, a buffer, and optionally one or more stabilizers for maintaining the activity of the therapeutic agent.
• the pH is raised to above 5.5 by the addition of a solution containing about 3 mM sodium taurocholate as the surfactant, about 0.75 mM phosphatidylcholine as the lipid, about 106 mM sodium chloride, and about 28 mM sodium phosphate adjusted with NaOH to pH 6.5.
• the pH is raised to above 5.0 using a buffer such as acetate, succinate, citrate, histidine, phosphate, Tris, or the like, or using a base such as sodium hydroxide.
• a buffer such as acetate, succinate, citrate, histidine, phosphate, Tris, or the like
• the pH is lowered in step (b) by the addition of HC1.
• the method further includes lyophilizing the formulation resulting from step (b).
• the therapeutic agent has a molecular weight of less than about 10000 Daltons and the resulting formulation includes a plurality of nanoparticles having a mean particle size of about 50 nm or less. In some embodiments, the therapeutic agent has a molecular weight of more than about 10000 Daltons and the resulting formulation includes a plurality of nanoparticles having a mean particle size of about 100 nm or less.
• the pH-sensitive polymer is an anionic co-polymer of methylmethacrylic acid and methacrylic acid, such as poly(methacrylic acid-co-methyl methacrylate) 1 : 1, poly(methacylic acid-co-methyl methacrylate) 1 :2.
• the pH-sensitive polymer is an anionic polymer of hydroxypropyl methylcellulose, such as hydroxypropyl methylcellulose phthalate, or hydroxypropyl methylcellulose acetate succinate.
• the therapeutic agent is a peptide, protein, nucleic acid, small molecule drug, or a combination thereof.
• an oral formulation of a therapeutic agent is prepared by the above described method.
• Another aspect of the invention is method of treating a disease, or to aid in treating a disease.
• the method includes orally administering any of the compositions described above to a subject in need thereof.
• the composition includes a therapeutic agent that aids in treating the disease.
• the therapeutic agent is insulin and the disease is diabetes, metabolic syndrome related to insulin deficiency, or diabetic ketoacidosis in an infant, child, or adolescent.
• the therapeutic agent is an antitumor antibody and the disease is cancer.
• the therapeutic agent is an anti-inflammatory antibody and the disease is an inflammatory disease.
• An oral formulation of a therapeutic agent comprising a plurality of nanoparticles having a mean particle size of 50 nm or less, the nanoparticles comprising a pH- sensitive polymer and a therapeutic agent having a molecular weight of about 10000 Daltons or less.
• the nanoparticles consist essentially of said pH-sensitive polymer and said therapeutic agent.
• nanoparticles further comprise a component selected from the group consisting of a surfactant, a lipid, a mucoadhesive polymer, and a combination thereof.
• nanoparticles have a mean particle size from about 10 nm to about 30 nm.
• the therapeutic agent is a peptide, a protein, a nucleic acid, a small molecule drug, or a combination thereof.
• nanoparticles have a mean particle size of about 45 nm or less, or about 40 nm or less, or about 35 nm or less, or about 30 nm or less, or about 25 nm or less, or from about 5 nm to about 50 nm, or from about 5 nm to about 20 nm, or from about 5 nm to about 30 nm, or from about 5 nm to about 40 nm, or from about 10 nm to about 40 nm, or from about 20 nm to about 40 nm, or from about 20 nm to about 50 nm.
• An oral formulation of a therapeutic agent comprising a plurality of nanoparticles having a mean particle size of 100 nm or less, the nanoparticles comprising a pH- sensitive polymer and a therapeutic agent having a molecular weight of more than 10000 Daltons.
• nanoparticles further comprise a component selected from the group consisting of a surfactant, a lipid, a mucoadhesive polymer, and a combination thereof.
• any of embodiments 13-17, wherein the therapeutic agent is selected from the group consisting of a protein, a nucleic acid, an antibody, a vector, a virus-like particle, a vaccine, and a combination thereof.
• the therapeutic agent is an antibody selected from the group consisting of anti-EGFR, anti-Her2, anti-RSV, anti-interleukin, and anti-TNF, or selected from the group consisting of cetuximab, trastuzumab, palivizumab, tocilizumab, and adalimumab.
• a method of preparing an orally administrable formulation of a therapeutic agent comprising the steps of:
• step (a) comprises providing an aqueous solution comprising the therapeutic agent and pH-sensitive polymer at a pH below 5.0 and then raising the pH to 5.0 or above by the addition of a solution containing a surfactant, a lipid, and a buffer.
• step (c) lyophilizing the formulation resulting from step (b).
• the therapeutic agent is selected from the group consisting of a peptide, a protein, a nucleic acid, an antibody, a vector, a vaccine, and a combination thereof.
• a method to aid in treating a disease comprising orally administering the formulation of any of embodiments 1-23 to a subject in need thereof, wherein the formulation comprises a therapeutic agent that aids in treating said disease.
• the therapeutic agent is insulin and the disease is selected from the group consisting of diabetes, metabolic syndrome related to insulin deficiency, and diabetic ketoacidosis in an infant, child, or adolescent.
• Fig. 1 is a flowchart of a solvent-free method for making nanoparticulate oral delivery formulations according to the invention.
• Fig. 2 is a flowchart of a modified solvent-free method for making nanoparticulate oral delivery formulations according to the invention.
• Fig. 3 is a flowchart of a solvent-based method for making nanoparticulate oral delivery formulations according to the invention.
• Fig. 4 shows the time course of insulin release from an insulin formulation produced by the solvent-free method.
• the release medium was simulated gastric fluid (SGF) or simulated intestinal fluid (SIF). Insulin concentration is expressed in units of area under the curve (AUC) for the insulin peaks obtained by HPLC fractionation of the medium.
• Fig. 5 shows the time course of insulin release from an insulin formulation in fasted state simulated gastric fluid (FaSSGF) and fasted state simulated intestinal fluid (FaSSIF). The amount of insulin released was measured using an insulin-specific ELISA.
• Fig. 6 shows the time course of insulin release from an insulin formulation in FaSSGF and FaSSIF using ELISA.
• Fig. 7 shows the time course of insulin release from an insulin formulation in FaSSGF and FaSSIF using HPLC.
• Fig. 8 shows particle size measurement using dynamic laser light scattering (DLS).
• Fig. 9 shows the time course of insulin release from an insulin formulation in FaSSGF and FaSSIF using ELISA.
• Fig. 10 shows the time course of insulin release from an insulin formulation in FaSSGF and FaSSIF using ELISA.
• Fig. 11 shows the time course of insulin release from an insulin formulation in FaSSGF and FaSSIF using HPLC.
• Fig. 12 shows the time course of insulin release from an insulin formulation in FaSSGF and FaSSIF using ELISA.
• Fig. 13 shows the time course of insulin release from an insulin formulation in FaSSGF and FaSSIF using HPLC.
• Fig. 14 shows particle size measurement using DLS.
• Fig. 15 shows the time course of insulin release from an insulin formulation in FaSSGF and FaSSIF using ELISA.
• Fig. 16 shows the time course of insulin release from an insulin formulation in FaSSGF and FaSSIF using HPLC.
• Fig. 17 shows a lyophilizati on pressure profile.
• Fig. 18 shows a lyophilizati on temperature profile.
• Fig. 19 shows changes in postprandial blood glucose of a human subject in response to administration of insulin formulations and to controls.
• Fig. 20 shows the mean normalized blood glucose of 3 dogs after administration of various insulin formulations.
• Fig. 21 shows the release profile of anti-EGFR antibody in pH 2.1 and pH 6.5 using size exclusion (SEC) HPLC.
• Fig. 23 shows the release profile of anti-RSV antibody in pH 2.1 and pH 6.5 using SEC-
• Fig. 24 shows the release profile of anti-RSV antibody in pH 2.1 and pH 6.5 using
• Fig. 25 shows the release profile of anti-TNF antibody in pH 2.1 and pH 6.5 using
• Fig. 26 shows the release profile of anti-IL6 antibody in pH 2.1 and pH 6.5 using ELISA.
• Fig. 27 shows the release profile of ascorbic acid in FASSIF and FASSIF measured spectrophotometrically using A280.
• Fig. 28 shows measurement of particle size of ascorbic acid-containing nanoparticles using DLS.
• Fig. 29 shows the release profile of albumin encapsulated by the solvent-based method.
• Fig. 30 shows the time course of insulin release from an insulin encapsulated by the solvent-based method.
• Fig. 31 shows the time course of insulin release from a nanoparticle formulation containing insulin and 2% alginic acid encapsulated by the solvent-based method.
• the present invention provides pH-sensitive nanoparticle and microparticle compositions, methods of making the compositions, and methods for the oral delivery of therapeutic agents to treat diseases or medical conditions.
• the methods and formulations of the invention enable the protection of a wide variety of therapeutic agents in the gastric environment by forming a stable association of a therapeutic agent with a pH-sensitive polymer in the form of nanoparticles.
• the nanoparticles allow pH-dependent absorption of the therapeutic agent in the small intestine, leading to high bioavailability.
• the nanoparticles of the invention provide a stable association between the polymer chains of the nanoparticles and the molecules of the therapeutic agent, wherein at low pH the therapeutic agent remains tightly associated with the polymer chains, thereby protecting the therapeutic agent from degradation at low pH.
• the pH-sensitive polymers used in the invention typically contain substituents that are neutral (protonated) at low pH but negatively charged (deprotonated) at neutral pH, leading to pH-dependent changes in particle size, such that the particles have nanoscale size at about neutral pH but microscale size at low pH. No external energy, such as sonication or heating, is necessary to generate the nanoparticles.
• the larger particle size at low pH may enhance protection of the therapeutic agent, whereas the smaller particle size at neutral pH promotes absorption of the therapeutic agent.
• the nanoparticles may entirely dissociate and their molecular components become completely solubilized at neutral pH. In other embodiments, the nanoparticles do not dissociate at neutral pH, but are of such small size as to allow good bioavailability by cellular absorption or paracellular transport.
• nanoparticle compositions of the invention are their very small size, which leads to higher bioavailability than obtained with previous particle compositions.
• the size of the nanoparticles at neutral pH is determined in part by the molecular size of the therapeutic agent. In general, the larger the molecular size of the therapeutic agent, the larger will be the size of the nanoparticles present at neutral pH. While in principle a continuum of nanoparticle sizes can be produced with methods of the invention, reflecting a continuum of molecular sizes of therapeutic agents, together with the pH dependence of the polymer, for convenience the nanoparticulate compositions are distinguished herein as being either "low molecular weight” or "high molecular weight” depending on the molecular weight of the therapeutic agent.
• the nanoparticulate formulation includes a plurality of nanoparticles having a mean particle size of 50 nm or less, or about 45 nm or less, or about 40 nm or less, or about 35 nm or less, or about 30 nm or less, or about 25 nm or less.
• particle size refers to the hydrodynamic diameter of a particle. Average hydrodynamic diameter can be determined, for example, using dynamic light scattering (DLS).
• the nanoparticles of low molecular weight embodiments have a mean particle size of less than about 50 nm, or from about 10 nm to about 30 nm, or from about 15 nm to about 25 nm.
• the nanoparticles have a mean particle size from about 5 nm to about 50 nm, or from about 5 nm to about 20 nm, or from about 5 nm to about 30 nm, or from about 5 nm to about 40 nm, or from about 10 nm to about 40 nm, or from about 20 nm to about 40 nm, or from about 20 nm to about 50 nm.
• the nanoparticles include a pH-sensitive polymer and a therapeutic agent having a molecular weight of about 10000 Daltons or less, or about 9000 Daltons or less, 8000 Daltons or less, 7000 Daltons or less, 6000 Daltons or less, 5000 Daltons or less, 4000 Daltons or less, 3000 Daltons or less, 2000 Daltons or less, or 1500 Daltons or less.
• the therapeutic agent has a molecular weight from about 1000 to about 10000 Daltons, or from about 1000 Daltons to about 5000 Daltons, or from about 1000 Daltons to about 3000 Daltons, or from about 1000 Daltons to about 4000 Daltons, or from about 500 Daltons to about 5000 Daltons, or from about 3000 Daltons to about 5000 Daltons, or from about 5000 Daltons to about 10000 Daltons.
• a low molecular weight form of the nanoparticle composition contains one or more therapeutic agents having a molecular weight from about 1000 Daltons to about 15000 Daltons, or from about 5000 Daltons to about 15000 Daltons, or from about 3000 Daltons to about 8000 Daltons.
• the nanoparticulate formulation includes a plurality of nanoparticles having a mean particle size of about 100 nm or less, or about 90 nm or less, or about 80 nm or less, or about 110 nm or less, or about 120 nm or less, or about 130 nm or less, or about 140 nm or less, or about 150 nm or less, or about 30 nm to about 90 nm, or about 30 nm to about 100 nm, or about 40 nm to about 100 nm, or about 50 nm to about 100 nm, or about 60 nm to about 90 nm.
• the nanoparticles include a pH-sensitive polymer and a therapeutic agent having a molecular weight of about 10000 Daltons or more, for example, 15000 Daltons or more, 20000 Daltons or more, 25000 Daltons or more, 30000 Daltons or more, 40000 Daltons or more, or 50000 Daltons or more.
• the therapeutic agent has a molecular weight of about 50000 Daltons or more, for example, 60000 Daltons or more, 70000 Daltons or more, 80000 Daltons or more, or 90000 Daltons or more.
• the therapeutic agent has a molecular weight of more than about 10000 Daltons, such as about 11000 Daltons to about 20000 Daltons, or to about 30000 Daltons, to about 40000 Daltons, to about 50000 Daltons, to about 70000 Daltons, to about 100000 Daltons, to about 150000 Daltons, to about 200000 Daltons, to about 300000 Daltons, or to about 500000 Daltons.
• the pH-dependent solubility of the nanoparticles of the invention is determined by the pH-dependent solubility of one or more polymers or co-polymers that are contained with the nanoparticles and form the matrix of the nanoparticles.
• a variety of pH-dependent polymers are known which are suitable for use in pharmaceutical compositions. Such polymers should be non-toxic, non-allergenic, available in pure form, and both physiologically and pharmacologically inert. Preferably they are also non-metabolizable.
• the pH-sensitive polymer is an anionic polymer possessing a plurality of carboxyl groups distributed periodically along the length of the polymer backbone.
• the pH-dependence of the aqueous solubility of the polymer, and also the size of nanoparticles or microparticles formed by the polymer can be finely tuned by adjusting the amount or distribution of carboxyl or other substituent groups on the polymer chain.
• the pH-sensitive polymer is a copolymer of methacrylic acid and an acrylic or methacrylic ester.
• the pH-sensitive polymer is a methacrylic acid- methylmethacrylate copolymer, or a methacrylic acid-ethyl acrylate copolymer.
• the pH-sensitive polymer is poly(methacrylic acid-co-methyl methacrylate) 1 : 1, poly(methacrylic acid-co-methyl methacrylate) 1 :2, or a combination of both, and the ratio of carboxyl groups to ester groups (carboxyl/ester ratio) of poly(methacrylic acid-co-methyl methacrylate) can be manipulated to control the polymer pH sensitivity.
• the pH-sensitive polymer is preferably a methylmethacrylate-methacrylic acid copolymer, for example a methylmethacrylate-methacrylic acid copolymer having a molar ratio of about 1 : 1 of methylmethacrylate to methacrylic acid.
• the pH-sensitive polymer has a molecular weight from about 60,000 to about 200,000 Daltons.
• the pH- sensitive polymer is a cellulose derivative, such as cellulose acetate phthalate (CAP), cellulose acetate succinate (CASE), cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate (or hypromellose phthalate) (HPMCP), or hydroxypropyl methylcellulose acetate succinate (or hypromellose acetate succinate) (HPMCAS), shellac gum, or polyvinyl acetate phthalate (PVAP).
• CAP cellulose acetate phthalate
• CASE cellulose acetate succinate
• CAT cellulose acetate trimellitate
• HPPMCP hydroxypropyl methylcellulose phthalate
• HPMCAS hydroxypropyl methylcellulose acetate succinate
• shellac gum or polyvinyl acetate phthalate (PVAP).
• the pH-sensitive polymer is preferably hydroxypropyl methylcellulose acetate succinate, for example having a molecular weight from about 10,000 Daltons to about 500,000 Daltons. All of the above-mentioned polymers may be used individually or in combination to achieve the desired pH sensitivity, to control drug release or particle size, and to improve bioavailability of the drug upon oral administration.
• a pH-dependent polymer for use in the invention is insoluble at acidic pH and soluble at neutral and/or alkaline pH.
• the pH-sensitive polymer is substantially soluble in water at about 37°C from pH of about 5.0 to pH about 8.0, or from about 4.5 to about 8.5, or from about 5.5 to about 8.0, or from about 6.0 to about 8.5, or from about 6.5 to about 8.5.
• the pH-sensitive polymer is also substantially insoluble in water at about 37°C from a pH of about 1.5 to pH about 3.5, or from about 1.0 to about 4.0, or from about 2.0 to about 4.0, or from about 1.0 to about 6.0, or from about 1.0 to about 6.5, or from about 1.0 to about 7.0, or from about 1.0 to about 7.5.
• release of a therapeutic agent refers to either the release of small nanoparticles containing associated therapeutic agent from microparticles containing associated therapeutic agent, or refers to the release of individual molecules of therapeutic agent from microparticles or nanoparticles,
• the release can be very rapid, such as within seconds or minutes, or it can be slow, taking hours or longer for a substantial amount of therapeutic agent to be released.
• An important parameter is the ability of the microparticles and/or nanoparticles to retain the therapeutic agent at acid pH.
• the therapeutic agent is released from the particles upon exposure of the particles to a solution of 0.01 N HCl at 23°C for about 6 h. In other embodiments, more than 40% by mass of the therapeutic agent is released from the particles upon exposure of the particles to a solution of phosphate-buffered saline at pH about 6.8 at about 23 °C for about 1 h.
• the mircoparticles/nanoparticles have both of these properties (i.e., very slow release at low pH and rapid and complete release at high pH.
• the therapeutic agent should be released to a high degree (such as more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, or more than 90%) within a physiologically or pharmacologically relevant timeframe (such as within 10 minutes, 30 minutes, 60 minutes, 90 minutes, or 120 minutes).
• a physiologically or pharmacologically relevant timeframe such as within 10 minutes, 30 minutes, 60 minutes, 90 minutes, or 120 minutes.
• the therapeutic agent should not be substantially released during the time required for transit through the stomach.
• less than 5% of the therapeutic agent is released from the particles in 2 hours at a pH of less than about 2.0.
• the mass ratio of therapeutic agent to pH-sensitive polymer is from about 10: 1 to about 1 : 12, for example, about 10: 1, about 9: 1, about 8: 1, about 7: 1, about 6: 1, about 5: 1, about 4: 1, about 3 : 1, about 2: 1, about 1 : 1, about 1 :2, about 1 :3, about 1 :4, about 1 :5, about 1 :6, about 1 :7, about 1 :8, about 1 :9, about 1 : 10, about 1 : 11, or about 1 : 12.
• the mass ratio is from about 5: 1 to about 1 :5, or from about 3 : 1 to about 1 :3, or from about 2: 1 to about 1 :2, or is about 1 : 1.
• the nanoparticles consist essentially of the pH-sensitive polymer and the therapeutic agent. In some embodiments, the nanoparticles and/or nanoparticle compositions and/or pharmaceutical compositions are essentially free of solvents. In other embodiments, the nanoparticles can further include one or more components such as buffers, surfactants, lipids, mucoadhesive polymers, stabilizing excipients, and combinations thereof.
• Additional components can be useful in maintaining solubility of the therapeutic agent during preparation of the nanoparticles or after release of the agent from the nanoparticles, or may be useful in preventing aggregation of the nanoparticles or promoting suspendability of the nanoparticles in aqueous solutions or water, and may also improve the bioavailability of the therapeutic agent. They may also improve the storability or useful half-life of the nanoparticles, and can help preserve the structure of the nanoparticles and/or bioavailability of the therapeutic agent after lyophilization.
• Mucoadhesive polymers can improve the adhesion of nanoparticles to the surface of the intestinal mucosa, leading to improved absorption into intestinal epithelial cells and eventually into the blood.
• Surfactants can include anionic surfactants, including sodium oleate, sodium caprylate, sodium dodecyl sulfate, deoxycholate or sodium deoxycholate, taurocholate, or sodium taurocholate, dioctyl sodium sulfosuccinate, and sodium stearyl fumarate; nonionic surfactants, including polyoxy ethylene ethers, polysorbate 80, and alkyl glycosides; and cationic surfactants, including quaternary ammonium compounds.
• anionic surfactants including sodium oleate, sodium caprylate, sodium dodecyl sulfate, deoxycholate or sodium deoxycholate, taurocholate, or sodium taurocholate, dioctyl sodium sulfosuccinate, and sodium stearyl fumarate
• nonionic surfactants including polyoxy ethylene ethers, polysorbate 80, and alkyl glycosides
• cationic surfactants including quaternary ammoni
• Lipids can include, for example, phospholipids (either neutral, cationic, or anionic), fatty acids (e.g., oleic acid, caprylic acid, linoleic acid, linolenic acid, sodium oleate, sodium linoleate, or sodium caprylate), fatty alcohols, and/or sterols.
• Lipids also include sphingolipids, including, but not limited to, sphingomyelin; glycosphingolipids including gangliosides, globocides and cerebrosides; and surfactant amines including, but not limited to, stearyl, oleyl and linoleyl amines.
• phospholipid is understood to be an amphiphilic derivative of glycerol, in which one of its hydroxyl groups is esterified with phosphoric acid and the other two hydroxyl groups are esterified with long-chain fatty acids that can be equal to or different from each other and can be saturated or unsaturated.
• a neutral phospholipid is generally one in which the other phosphoric acid hydroxyl is esterified by an alcohol substituted by a polar group (usually hydroxyl or amino) and whose net charge is zero.
• a phospholipid with a charge is generally one in which the other phosphoric acid hydroxyl is esterified by an alcohol substituted by a polar group and whose net charge is positive or negative.
• phospholipids examples include phosphatidic acid (“PA”), phosphatidylcholine (“PC”), phosphatidylglycerol (“PG”), phophatidylethanolamine (“PE”), phophatidylinositol ('”PI”), phosphatidylserine (“PS”), sphingomyelin (including brain sphingomyelin), lecithin, lysolecithin, lysophosphatidylethanolamine, cerebrosides, diarachidoylphosphatidylcholine (“DAPC”), didecanoyl-L-alpha-phosphatidylcholine (“DDPC), dielaidoylphosphatidylcholine (“DEPC”), dilauroylphosphatidylcholine (“DLPC”), dilinoleoylphosphatidylcholine, dimyristoylphosphatidylcholine (“DMPC”), dioleoyl
• diarachidoyl sphingomyelin didecanoyl sphingomyelin, dielaidoyl sphingomyelin, dilauroyl sphingomyelin, dilinoleoyl sphingomyelin, dimyristoyl sphingomyelin, sphingomyelin, dioleoyl sphingomyelin, dipalmitoyl sphingomyelin, distearoyl sphingomyelin, and l-palmitoyl-2-oleoyl- sphingomyelin.
• fatty acid means a compound whose structure is a carboxylic group attached to a hydrocarbon chain having one or more carbon atoms.
• the hydrocarbon chain may be saturated or unsaturated (i.e., alkyl, alkenyl or alkynyl hydrocarbon chains). Also, the hydrocarbon chain may be straight or branched. Moreover, in some embodiments, hydrogens in the hydrocarbon chain may be substituted.
• fatty alcohol means a compound whose structure is an alcohol group attached to a hydrocarbon chain having one or more carbon atoms.
• the hydrocarbon chain may be saturated or unsaturated (i.e., alkyl, alkenyl or alkynyl hydrocarbon chains).
• the hydrocarbon chain may be straight or branched.
• hydrogens in the hydrocarbon chain may be substituted.
• fatty acid salt means a compound formed from a reaction between a fatty acid and an inorganic/organic base.
• the term encompasses a compound formed from a reaction between a fatty alcohol and an inorganic/organic acid. Examples of such acids include sulfuric and phosphoric acid.
• the hydrocarbon chain of the fatty acid salt may be saturated or unsaturated (i.e., alkyl, alkenyl or alkynyl hydrocarbon chains).
• the hydrocarbon chain may be straight or branched.
• hydrogens in the hydrocarbon chain may be substituted.
• the mass ratio of lipid to pH-sensitive polymer is from about 1 : 10 to about 8: 1, for example, about 1 : 10, about 1 :9, about 1 :8, about 1 :7, about 1 :6, about 1 :5, about 1 :4, about 1 :3, about 1 :2, about 1 : 1, about 2: 1, about 3 : 1, about 4: 1, about 5: 1, about 6: 1, about 7: 1, or about 8: 1.
• Mucoadhesive polymers can include, for example, hydroxypropyl methylcellulose, alginic acid, and polyxamer.
• a mucoadhesive polymer has a molecular weight from about 10,000 Daltons to about 150,000 Daltons, or from about 10,000 Daltons to about 300,000 Daltons, or from about 10,000 Daltons to about 600,000 Daltons.
• the low molecular weight therapeutic agent is a peptide, protein, nucleic acid, small molecule drug (i.e., any kind of pharmaceutical agent having a molecular weight of 1500 Daltons or less), or a combination thereof.
• Peptides can include antitumor peptides (e.g., leuprolide), peptides that treat metabolic diseases (e.g., insulin glargine, glucagon- like peptide-1 receptor agonists), peptide hormones (e.g., EPO), anti-infectious agents, (e.g., telavancin, protease inhibitors), analgesic/anesthetic peptides (e.g., enkephalin), and antiinflammatory peptides.
• antitumor peptides e.g., leuprolide
• peptides that treat metabolic diseases e.g., insulin glargine, glucagon- like peptide-1 receptor agonists
• Proteins can include antitumor proteins (e.g., anti-VEGF agents, interferons, cytokines), proteins that treat metabolic diseases (e.g., insulin, glucagon), protein hormones (e.g., calcitonin, gonadotropin-releasing hormone), anti-infectious proteins (e.g., interferons), anti-inflammatory proteins (anti-TNF alpha agents), monoclonal antibodies, vaccines, enzymes, and enzyme inhibitors.
• Nucleic acids can include aptamers, small interfering RNAs, antisense oligonucleotides, and nucleic acids for gene editing and gene therapy, including viral vectors such as adenoviral vectors and lentiviral vectors.
• a preferred low molecular weight therapeutic agent is insulin.
• insulin refers to any naturally occurring or recombinant insulin. Accordingly, insulin for use in the invention includes, for example, insulin analogs and derivatives. Insulin from any suitable species can be used, such as human, pig, cow, dog, sheep. In a preferred embodiment, the insulin is recombinant human insulin. Naturally-occurring insulin or synthetic insulin can include monomeric, polymeric, and/or fibril-like insulin; it is understood that insulin molecules can take on different forms depending on pH.
• the therapeutic agent can be, for example, a protein, a nucleic acid, an antibody, a virus-like particle, a vaccine, or a combination thereof.
• Proteins can include antitumor proteins (e.g., anti-VEGF agents, interferons, cytokines), proteins that treat metabolic diseases (e.g., insulin, glucagon), protein hormones (e.g., calcitonin, gonadotropin-releasing hormone), anti-infectious proteins (e.g., interferons), anti-inflammatory proteins (anti-TNF alpha agents), polyclonal antibodies, monoclonal antibodies, vaccines, enzymes, and enzyme inhibitors.
• Nucleic acids include aptamers, small interfering RNAs, antisense oligonucleotides, gene editing and gene therapy.
• Antibodies are preferred high molecular weight therapeutic agents for use in the invention. Such and antibody can be polyclonal, monoclonal, human, humanized, chimeric, or recombinant, and also can be an antigen-binding fragment of such an antibody. Monoclonal antibodies can be naturally occurring or recombinant immunoglobulin molecules. An antibody can be any class of immunoglobulin, such as IgG, IgM, IgA, IgD or IgE.
• Antibodies for use in the invention include antibody analogs and derivatives, such as antibody fragments (Fab, Fc, Fv), diabodies, triabodies, minibodies, nanobodies, single-domain antibodies such as scFv, and antibody fusion proteins.
• Preferred antibodies include antibodies that bind to EGFR, Her2, RSV, interleukin, and TNF, including cetuximab, trastuzumab, palivizumab, tocilizumab, and adalimumab, respectively.
• a composition of the invention is a pharmaceutical composition containing a plurality of any of the nanoparticles or microparticles of the invention, either in suspension in an aqueous medium or as a lyophilized material, together with one or more excipients, such as one or more carriers, fillers, binders, buffers, glidants, solutions, solvents, surfactants, electrolytes, salts, lubricants, disintegrants, swelling agents, antioxidants, or additional therapeutic agents not in nanoparticulate or microparticulate form.
• the pharmaceutical composition also can contain two or more different types of nanoparticles of the invention, having different therapeutic agents, or the same therapeutic agent in different nanoparticles having different release profiles.
• the pharmaceutical composition also can contain "blank" pH-dependent nanoparticles that carry no therapeutic agent.
• the pharmaceutical composition preferably is formulated for oral delivery, such as in the form of a capsule, tablet, or oral suspension in liquid. Specific embodiments of the pharmaceutical compositions are formulated for pediatric uses.
• the formulation is a beverage or is suitable for reconstitution as a beverage, such as a fruit or vegetable juice, such as orange juice, or in a diary product such as milk or yogurt.
• Fillers include lactose, saccharose, glucose, starch, microcrystalline cellulose, microfine cellulose, mannitol, sorbitol, calcium hydrogen phosphate, aluminum silicate, amorphous silica, sodium chloride, starch, and dibasic calcium phosphate dehydrate.
• the filler is not water soluble, although it may absorb water.
• the filler is a spheronization aid.
• Spheronization aids can include one or more of crospovidone, carrageenan, chitosan, pectinic acid, glycerides, ⁇ -cyclodextrin, cellulose derivatives, microcrystalline cellulose, powdered cellulose, polyplasdone, crospovidone, and polyethylene oxide.
• the filler includes microcrystalline cellulose.
• Binders include cellulose ethers, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, propyl cellulose, hydroxypropyl cellulose, lower- substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose (hypromellose, e.g., hypromellose 2910, METHOCEL E), carboxymethyl cellulose, starch, pregelatinized starch, acacia, tragacanth, gelatine, polyvinyl pyrrolidone (povidone), cross-linked polyvinyl pyrrolidone, sodium alginate, microcrystalline cellulose, and lower- substituted hydroxypropyl cellulose.
• the binders are selected from wet binders.
• the binder is selected from cellulose ethers, e.g., hypromellose.
• Disintegrants include starch, sodium cross-linked carboxymethyl cellulose, carmellose sodium, carmellose calcium, cross-linked polyvinyl pyrrolidone, sodium starch glycolate, low- substituted hydroxypropyl cellulose, and hydroxypropyl starch.
• Glidants include polyethylene glycols of various molecular weights, magnesium stearate, calcium stearate, calcium silicate, fumed silicon dioxide, magnesium carbonate, magnesium lauryl sulfate, aluminum stearate, stearic acid, palmitic acid, cetanol, stearol, and talc.
• Lubricants include stearic acid, magnesium stearate, calcium stearate, aluminum stearate, and siliconized talc.
• a pharmaceutical composition also can include an aqueous medium, such as any water- based medium, e.g., water, saline solution, sugar solution, transfusion solution, or a buffer.
• An aqueous medium may contain one or more water-soluble organic solvents, such as ethanol, methanol, tetrahydrofuran, dimethylsulfoxide, etc., although in certain embodiments the pharmaceutical composition is solvent free.
• An aqueous medium is preferably sterile and suitable for use as a carrier of an active agent, and preferably has low concentrations of water- soluble organic solvents, if organic solvents are present at all. Examples of aqueous media include, but are not limited to, water for injection, saline solution, Ringer's solution, D5W, or other solutions of water-miscible substances such as dextrose and other electrolytes.
• a pharmaceutical composition may contain a pharmaceutically acceptable salt, such as a salt prepared from pharmaceutically acceptable non-toxic acids or bases, including inorganic acids and bases, and organic acids and bases.
• a pharmaceutically acceptable base addition salts for the compositions provided herein include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc, or organic salts made from lysine, ⁇ , ⁇ '- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
• Suitable nontoxic acids include inorganic and organic acids such as acetic, alginic, anthranilic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, formic, fumaric, furoic, galacturonic, gluconic, glucuronic, glutamic, glycolic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phenylacetic, phosphoric, propionic, salicylic, stearic, succinic, sulfanilic, sulfuric, tartaric acid, and p-toluenesulfonic acid.
• Non-toxic acids include hydrochloric, hydrobromic, phosphoric, sulfuric, and methanesulfonic acids. Examples of specific salts thus include hydrochloride and mesylate salts.
• the invention provides several methods for making oral formulations of therapeutic agents.
• One method is a solvent-free method that involves association of the therapeutic agent with a pH-sensitive polymer to form nanoparticles containing the agent and the polymer.
• An aqueous solution is provided that contains a soluble therapeutic agent and a pH-sensitive polymer.
• the solution initially has a pH of about 5.0-5.5, and subsequently the pH of the solution is lowered to less than about 4.0, whereby the therapeutic agent and the polymer associate.
• the polymer-therapeutic agent complex so formed remains stable at acidic pH. When the complex is orally administered to a mammalian subject, the therapeutic agent is not substantially degraded in the gastric environment, and is released in bioavailable form in the higher pH intestinal environment.
• the therapeutic agent and the polymer are first added to an aqueous acidic solution (i.e., pH below about 5.5) and the pH is then raised to above about 5.5 by the addition of a solution containing a surfactant, a lipid, and a buffer such as acetate, succinate, citrate, histidine, phosphate, Tris, or the like, or a base such as sodium hydroxide.
• a solution containing a surfactant, a lipid, and a buffer such as acetate, succinate, citrate, histidine, phosphate, Tris, or the like, or a base such as sodium hydroxide.
• the polymer is insoluble at acidic pH and forms microparticles or nanoparticles (depending on the pH) associated with the therapeutic agent.
• the microparticles become small nanoparticles in the aqueous solution at a pH above 5.5, and in some embodiments the nanoparticles dissociate, releasing soluble therapeutic agent in molecular form or in a form not associated with particles of the polymer.
• the pH is raised to above 5.5 by the addition of a solution containing about 3 mM sodium taurocholate, about 0.75 mM phosphatidylcholine, about 106 mM sodium chloride, and about 28 mM sodium phosphate adjusted with NaOH to about pH 6.5.
• the pH is then lowered to less than about 4.0 by the addition of HCl.
• the therapeutic agent is insulin
• the nanoparticles formed have a small size below 50 nm, preferably below 30 nm, such as average size of about 18 nm, and the formation of the nanoparticles achieves about 100% association of the insulin with nanoparticles.
• the formulation may then be lyophilized, stored, and later reconstituted in an aqueous medium for oral administration.
• the lyophilized nanoparticles can be formulated as a suspension, capsule, or tablet dosage form for oral administration.
• the lyophilized nanoparticles are released upon reconstitution as nanoparticles of the same or similar size compared to prior to lyophilization.
• the nanoparticles thus formed will not dissociate and the therapeutic agent will not be released in acidic pH, even if the agent is one that is highly soluble at acidic pH, such as insulin.
• the therapeutic agent and the polymer are added to a first aqueous medium suitable for formulating the therapeutic agent, and a second aqueous medium containing a buffer such as acetate, succinate, citrate, histidine, phosphate, Tris, or the like, or a base such as sodium hydroxide, and having a pH of about 6.5, is added to the first aqueous medium to raise the pH to above 5.0 and to form a third aqueous medium.
• the third aqueous medium is then lyophilized. Nanoparticles are formed prior to the lyophylization process, and are still present following reconstitution of the lyophilized material.
• the nanoparticles thus formed will not dissolve or dissociate and the therapeutic agent will not be released from particles at the acidic pH of the gastric environment, even if the agent is highly soluble at acidic pH.
• the lyophilized nanoparticles can be formulated as a suspension, capsule, or tablet dosage form for oral administration.
• the concentration of the therapeutic agent in the aqueous medium is from about 0.05% to about 1.0% w/v, and more preferably from about 0.1% to about 0.3% w/v. In preferred embodiments of the above described solvent-free methods, the concentration of the polymer in the aqueous medium is from about 0.5% to about 10% w/v, and more preferably from about 1.0% to about 3.0% w/v.
• Another aspect of the invention is a solvent-based method for preparing an orally administrable formulation of a therapeutic agent.
• the method includes adding one volume of an aqueous medium containing the therapeutic agent to about 2-10 volumes of an aqueous medium containing a pH-sensitive polymer dissolved in a water-miscible non-aqueous solvent, such as an organic solvent, whereby the therapeutic agent and pH-sensitive polymer form nanoparticles or microparticles containing the therapeutic agent.
• the suspension may then be centrifuged, and the precipitated nanoparticles or microparticles collected for storage or resuspension in another aqueous medium.
• the concentration of the therapeutic agent in the aqueous solution is from about 0.05% to about 1.0% w/v, and more preferably from about 0.1% to about 0.3% w/v. In preferred embodiments, the concentration of the polymer in the aqueous solution is from about 0. 5% to about 10% w/v, and more preferably from about 1.0% to about 3.0% w/v.
• the water-miscible solvent can be any polar organic solvent, such as a linear, branched, or cyclic alcohol having between 1 and 6 carbon atoms, or it can contain at least one ketone, diketone, unsaturated ketone or cycloketone.
• the solvent is ethanol.
• Another aspect of the invention is a method of treating a disease or medical condition, or to aid in treating a disease or medical condition.
• the method includes orally administering a composition, such as a pharmaceutical composition, containing a nanoparticle formulation according to the invention, to a subject in need thereof.
• the formulation comprises a therapeutic agent that aids in treating said disease.
• the therapeutic agent is one that would be degraded or poorly absorbed if orally administered alone or using a conventional oral pharmaceutical formulation.
• the subject can be a mammal, such as a human.
• the therapeutic agent is insulin
• an insulin-containing composition of the invention is administered orally to treat diabetes, metabolic syndrome related to insulin deficiency, or diabetic ketoacidosis in an infant, child, or adolescent.
• the diabetes can be Type 1 or Type 2, and the subject can be any mammal or human in need of insulin administration.
• the oral administration of a composition of the invention can replace all or part of the conventional insulin therapy (e.g., insulin administered parenterally) of the subject.
• the therapeutic agent is an antitumor antibody (i.e., an antibody that leads to death of tumor cells by any mechanism), and it is administered to a subject to treat cancer in the subject.
• Antitumor antibodies include, but are not limited to anti-EGFR (e.g., cetuximab), anti-Her2 (e.g., trastuzumab), anti-RSV (e.g., palivizumab), anti-interleukin-(e.g., tocilizumab),.
• the cancer can be any cancer susceptible to treatment with one or more antibodies, such as breast, colorectal, or head and neck cancer.
• the therapeutic agent is an anti-inflammatory antibody and the disease is an inflammatory disease.
• Anti-inflammatory antibodies include, but are not limited to, antibodies against tumor necrosis factor (TNF) and interleukin-6 (IL-6) receptor antagonists.
• Inflammatory diseases include, but are not limited to, Crohn's disease, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
• the nanoparticles or microparticles formed by this method can be employed in any dosage form, including pills, tablets, capsules, drinks, liquid suspensions or lyophilized powder.
• This composition can be employed by any route of administration, including oral, inhalational, buccal, sublingual, nasal, suppository or parenteral.
• the formulation is for enteral administration, and even more preferably, oral administration.
• Fasted State Simulated Gastric Fluid (FaSSGF). Human FaSSGF was obtained from
• Biorelevant (London, UK). It contained 0.08 mM sodium taurocholate, 0.02 mM lecithin, 34.2 mM sodium chloride, and 25.1 mM hydrochloric acid. The pH of the solution was 1.6.
• Fasted State Simulated Intestinal Fluid Human FaSSIF was obtained from Biorelevant (London, UK). It contained 3 mM sodium taurocholate, 0.75 mM lecithin, 105.9 mM sodium chloride, 28.4 mM monobasic sodium phosphate, and 8.7 mM sodium hydroxide. The pH of the solution was 6.5.
• a therapy agent was dissolved and a pH-sensitive polymer was suspended in an acidic aqueous medium in which the therapeutic agent is soluble. Then, the pH was raised to 5.5 or higher by the addition of a solution containing 3 mM sodium taurocholate, 0.75 mM phosphatidylcholine, 106 mM sodium chloride, and 28 mM sodium phosphate, or the pH was raised to above 5.0 using a buffer such as acetate, succinate, citrate, histidine, phosphate, Tris, or the pH was adjusted with NaOH to 6.5. At pH 6.5, nanoparticles of the polymer were present. Subsequently, the pH was lowered to less than 4.0 with HC1 so as to tightly associate the therapeutic agent with the particles. Optionally, this suspension was then lyophilized.
• a high molecular weight therapeutic agent and a pH-sensitive polymer were mixed in an aqueous medium, to which a solution at pH 6.5 was subsequently added, forming nanoparticles with associated therapeutic agent, and the suspension was then lyophilized. The lyophilized sample was then reconstituted with an appropriate aqueous solution or buffer.
• a pH-sensitive polymer was solubilized in 100% ethanol to achieve a final concentration of about 1% to about 5% in solution.
• One volume of therapy agent in an aqueous solution was then added to 2-10 volumes of the organic solution containing the polymer.
• the solution was then centrifuged, and the precipitated nanoparticles were collected.
• a pH-sensitive polymer was solubilized in 100% ethanol to achieve a final concentration of about 1% to about 5% in solution.
• the so prepared therapeutic agent was added to 2-10 volumes of the organic solution containing the polymer, whereupon the polymer became associated with the precipitated therapeutic agent.
• the solution was then centrifuged, and nanoparticles containing the polymer and therapeutic agent were collected.
• ELISA Insulin Enzyme-Linked Immunosorbent Assay
• HPLC Insulin High Performance Liquid Chromatography
• Lyophilization For lyophilization, aliquots of solution were frozen at -50°C for 2 hours and then heated to 20°C with a ramp rate of 1 °C, at a pressure of 75 mTorr. Lyophilization was carried out until the Pirani gauge in contact with the samples reached 75 mTorr or less.
• Table 2 shows the composition of various nanoparticulate formulations that were made containing insulin as the therapeutic agent and EUDRAGIT L 100 as the pH-sensitive polymer. The formulations are discussed further in the examples below.
• the composition of insulin Formulation 1 is described in Table 2.
• the formulation was lyophilized, and 10 mg of the lyophilized powder (containing 1 mg insulin) was then reconstituted with 1 mL of the pH 6.5 buffer, forming nanoparticles. 100 ⁇ ⁇ of IN HCl was then added to the solution, thereby precipitating particles containing polymer (EUDRAGIT L 100) and insulin. HPLC analysis of the supernatant after centrifugation did not show any insulin, even though insulin is highly soluble in HCl, demonstrating that the insulin had become tightly associated with the particles.
• the size of the resuspended particles was analyzed using a Zetasizer (Malvern Instruments, Malvern, UK) and the software provided by the manufacturer.
• the resuspended particles had a Z average diameter of 20.76 nm.
• Formulation 3 was prepared following the solvent-free method using EUDRAGIT S-100 as polymer. When the pH of the solution was lowered to 3.5 the particles were not soluble. When the particles were transferred to PBS at pH 7.2, the precipitated particles became completely suspended or soluble, providing complete recovery of the insulin in PBS. Example 5. Reconstitution of Lyophilized Formulation in Orange Juice.
• Formulation 4 was prepared following the solvent-free method. When the pH was lowered to 3.5, the particles were not soluble, even though insulin is highly soluble in acidic pH. The particles were precipitated by centrifugation, and the precipitate was then solubilized in PBS at pH 7.2, with complete recovery of the insulin content based on RP-HPLC analysis. The precipitate was also reconstituted in ordinary, commercially available orange juice, and analysis of the orange juice showed that there was no free insulin in the liquid. However, when the pH was adjusted to 6.0, insulin-containing particles remained in the supernatant. This result suggests that the formulation, as reconstituted in orange juice or another fruit juice or acid drink, may be used as a pediatric formulation for diabetic patients.
• Example 6 Insulin Nanoparticle Formulations Containing Mucoadhesive Polymers.
• Formulation 5 was prepared following the solvent-free method. The formulation was then divided into 1.2 mL aliquots in 3-mL flint glass vials and lyophilized. HPLC analysis showed that the reconstituted lyophilized powder release Insulin completely, as the polymer entrapped with the insulin is soluble at pH 5.9.
• Formulation 6 containing the mucoadhesive polymer poloxamer, was prepared following the modified solvent-free method. The pH was adjusted to 3.5. The formulation was then divided into 1.2 mL aliquots in 3-mL flint glass vials and lyophilized. HPLC analysis showed that the reconstituted lyophilized powder does not release Insulin, as the polymer entrapped with the insulin is not soluble at pH 3.5.
• Formulation 7 containing the mucoadhesive polymer poloxamer, was prepared following the solvent-free method. The formulation was then divided into 1.2 mL aliquots in 3-mL flint glass vials and lyophilized. HPLC analysis showed that the reconstituted lyophilized powder release Insulin completely, as the polymer entrapped with the insulin is soluble at pH 5.9.
• Formulation 8 containing the mucoadhesive polymers alginate, hypromellose, and poloxamer, was prepared following the modified solvent-free nanoparticle formation method. The formulation was then divided into 1.2 mL aliquots in 3-mL flint glass vials and lyophilized. The final pH was 5.9. HPLC analysis showed that the reconstituted lyophilized powder release Insulin completely, as the polymer entrapped with the insulin is soluble at pH 5.9.
• Formulation 9 containing caprylic acid as permeability enhancer, was prepared by adding insulin and EUDRAGIT to an aqueous acidic solution, followed by the addition of NaOH, and then of the pH 6.5 buffer. To this solution, the permeability enhancer caprylic acid was added, and the pH of the formulation was adjusted to 5.6. The mean particle size of the formulation was 23 nm. One mL aliquots of the formulation were distributed in 20 mL vials and lyophilized. HPLC analysis showed that the reconstituted lyophilized powder release Insulin completely, as the polymer entrapped with the insulin is soluble at pH 5.6.
• Formulation 10 containing oleic acid as permeability enhancer, was prepared by adding insulin and Eudragit to an aqueous acidic solution, followed by the addition of NaOH, and then of the pH 6.5 buffer. To this solution, the permeability enhancer oleic acid was added, and the pH of the formulation reached 5.6. The particle size of the formulation was 18.6 nm. One mL aliquots of the formulation were distributed in 20 mL vials and lyophilized. HPLC analysis showed that the reconstituted lyophilized powder release Insulin completely, as the polymer entrapped with the insulin is soluble at pH 5.9.
• Example 8 Insulin Release from Lyophilzed Nanoparticle Formulations Reconstituted with FaSSIF or FaSSGF.
• Formulation 11 had a mean particle size of 18.28 nm as measured by DLS. 1 ml samples were distributed in two 20 mL vials and lyophilized. One vial was reconstituted with FaSSGF, and the pH was adjusted to less than 2.0. The second vial was reconstituted with FaSSIF at pH 6.5. The insulin release profile was monitored using an insulin-specific ELISA for 24 hours. At each time point, the samples were centrifuged at 10,000 rpm for 5 minutes and the supernatant was assayed for its insulin content by ELISA. The release profile, shown in Fig. 5, indicated that insulin was released into the supernatant only at pH 6.5 and not at the acidic pH of less than 2.0.
• Formulation 12 containing the mucoadhesive polymer HPMC, had a mean particle size of 23.11 nm as measured by DLS. 1 ml aliquots were distributed in two 20 mL vials and lyophilized. One vial was reconstituted with FaSSGF, and the pH was adjusted to less than 2.0. The second vial was reconstituted with FaSSIF at pH 6.5. The insulin release profile was monitored for 24 hours. At each time point, the samples were centrifuged at 10,000 rpm for 5 minutes and the supernatant was assayed for its insulin content using both HPLC and ELISA. Figs. 6 and 7 show the release profile determined by the two different methods. Both FIPLC and ELISA indicated that insulin was released into the supernatant only at pH 6.5, and not at the acidic pH of less than 2.0, with the inclusion in the nanoparticles of the mucoadhesive polymer.
• Formulation 13 containing the mucoadhesive polymer alginate had a mean particle size of 18.79 nm as measured by DLS (Fig. 8). 1 ml aliquots were distributed in two 20 mL vials and lyophilized. One vial was reconstituted with FaSSGF, and the pH was adjusted to less than 2.0. The second vial was reconstituted with FaSSIF at pH 6.5. The insulin release profile was monitored for 24 hours by ELISA. At each time point, the samples were centnfuged at 10,000 rpm for 5 minutes and the supernatant was assayed for its insulin content. Fig. 9 shows the release profile. Insulin was released into the supernatant only at pH 6.5, and not at the acidic pH of less than 2.0, with the inclusion of alginate in the nanoparticles.
• Formulation 14 containing the mucoadhesive polymer chitosan, had a mean particle size of 1577 nm as measured by DLS.
• the large particle size may have been due to insolubility of chitosan at pH 6.5.
• 1 ml aliquots were distributed in two 20 mL vials and lyophilized.
• One vial was reconstituted with FaSSGF, and the pH was adjusted to less than 2.0.
• the second vial was reconstituted with FaSSIF at pH 6.5.
• the insulin release profile was monitored for 24 hours. At each time point, the samples were centrifuged at 10,000 rpm for 5 minutes and the supernatant was assayed for its insulin content by both ELISA and and HPLC.
• Figs. 10 and 11 show the release profile for both methods. Insulin was released into the supernatant only at pH 6.5, and was not released at the acidic pH of less than 2.0, with the inclusion of chitosan in the nanoparticle
• One ml aliquots were distributed in two 20 mL vials and lyophilized.
• One vial was reconstituted with FaSSGF, and the pH was adjusted to less than 2.0.
• the second vial was reconstituted with FaSSIF at pH 6.5.
• the insulin release profile was monitored for 24 hours. At each time point, the samples were centrifuged at 10,000 rpm for 5 minutes and the supernatant was assayed for its insulin content by ELISA and HPLC.
• Figs. 12 and 13 show the release profile. Insulin was released into the supernatant only at pH 6.5 and not at the acidic pH of less than 2.0 with the inclusion in the nanoparticles of caprylic acid.
• Formulation 16 containing oleic acid as permeability enhancer, had a mean particle size of 18.55 nm as measured by DLS (Fig. 14).
• One ml aliquots were distributed in two 20 mL vials and lyophilized.
• One vial was reconstituted with FaSSGF, and the pH was adjusted to less than 2.0.
• the second vial was reconstituted with FaSSIF at pH 6.5.
• Insulin release profile was monitored for 24 hours. At each time point, the samples were centrifuged at 10,000 rpm for 5 minutes and the supernatant was assayed for its insulin content by ELISA and FIPLC.
• Figs. 15 and 16 show the release profile. Insulin was released into the supernatant only at pH 6.5 and not at acidic pH of less than 2.0 with the inclusion in the nanoparticles of oleic acid.
• the efficacy of the formulation prepared by the solvent-based method was tested on a human subject who had type 2 diabetes and was taking a daily dose of 100 mg of metformin and 42 units of insulin at night. This medication protocol was considered as the positive control. For the negative control, the medication was stopped altogether for a day.
• the nanoparticle formulation was prepared as follows. 212 mg of insulin was weighed in a 150 mL beaker, followed by the addition of 5 mL of 0.01N HC1 to dissolve the insulin. Then, 1.072 g of EUDRAGIT L 100 in ethanol was added, followed by 105 mL of pH 6.5 buffer. The pH of the mixture was 5.71; it was then adjusted either to 5.95 using 5N NaOH (to yield Formulation 16) or to pH 3.3 using HC1 (to yield Formulation 17). 16 mL of each formulation was dosed into 6 50-mL vials, partially stopped with rubber stoppers, and lyophilized.
• the completion of the lyophilization was considered to be when the pressure measured by the Pirani gauge in contact with the sample reached the shelf set pressure (Figs. 17 and 18).
• the formulations were then reconstituted with 15 mL of water for injection to obtain a final concentration of 2 mg/mL. 15 mL of this formulation containing 2 mg/mL of insulin was taken orally by the subject, one formulation per night. All medications were taken immediately after a meal. Blood sugar levels were measured using a OneTouch Ultra® glucose meter with OneTouch Ultra® test strips (LifeScan, Inc.) two hours after the meal. The first reading was considered time 0.
• the glycemia of the three dogs after oral administration of the oral insulin formulation ranged from 80-98% of control glucose levels 6 hours after feeding.
• the subcutaneous administration of HUMULIN resulted in 80-134% of control glucose levels, thus suggesting prolonged maintenance of lower glycemia after oral administration of the nanoparticle insulin formulation compared to subcutaneous administration of HUMULIN.
• Oral administration of Formulation 16 resulted in normalized blood glucose levels for two of the three dogs within 2 hours postdose.
• Administration of HUMULIN resulted in lower glycemia within 1 hour postdose, but higher glycemia 3-6 hours postdose (120% to 174% of control values) when compared to Day 1 (non-dosed) values.
• ERBITUX is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of head and neck cancer and colorectal cancer.
• the recommended initial dose is 400 mg/m 2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min).
• Cetuximab is commercialized as a 5 mg/mL solution containing 8.48 mg/mL sodium chloride, 1.88 mg/mL sodium phosphate dibasic heptahydrate, 0.41 mg/mL sodium phosphate monobasic monohydrate, and water for injection, USP. 400 ⁇ of cetuximab in this dosage form was added to 20 mg EUDRAGIT L 100 in a 10 mL vial, followed by 2 mL of pH 6.5 buffer (Table 4).
• This solution was aliquoted in 1.2 mL samples which were placed in 10 mL vials and lyophilized.
• One sample was reconstituted with 1 mL of FaSSGF and the second sample was reconstituted with 1 mL of FaSSIF.
• 120 ⁇ samples were taken at 0, 1, 2, 4, 8 and 24 hours, placed in 1.5 mL centrifuge tubes and centrifuged at 10,000 rpm for 5 minutes. 40 ⁇ of the supernatant of each sample was injected for size-exclusion chromatography-HPLC analysis.
• SEC-HPLC was conducted using a Tosohaas G3000SWXL column.
• HERCEPTF (trastuzumab) is indicated for adjuvant treatment of breast cancer.
• trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for intravenous administration.
• Each commercial multi-use vial of trastuzumab contained 440 mg trastuzumab, 400 mg ⁇ ,, ⁇ -trehalose dihydrate, 9.9 mg L-histidine HC1, 6.4 mg L-histidine, and
• EUDRAGIT L 100 in a 10 mL vial. To this solution, 7.5 mL of pH 6.5 buffer was added. Then,
• FaSSGF (pH 1.5-2) or FaSSIF (pH 6.5)
• the final pH was adjusted to pH 1.5 and 6.5 respectively, due to the buffering capacity of trastuzumab formulation buffer.
• the samples were then diluted 20,000 fold with the ELISA assay buffer. Detection and quantification of trastuzumab was then conducted using Human IgG total Ready-Set-Go! ® kits (Affymetrix/eBioscience Inc., San Diego, CA, USA). No release of trastuzumab into the supernatant at acidic pH was observed even after 24 hours. However, at pH 6.5, most of the antibody was released into the supernatant within 1 hour ( Figure 22).
• SYNAGIS is a humanized monoclonal antibody (IgGlk) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).
• Each 100 mg single-dose vial of palivizumab liquid solution contains 100 mg of palivizumab, 3.9 mg of histidine, 0.1 mg of glycine, and 0.5 mg of chloride in a volume of 1 mL at a pH of approximately 6.0.
• the dosage form is an intramuscular injection.
• 98 ⁇ of palivizumab was added to 98 mg EUDRAGIT L 100 in a 10 mL vial.
• Detection and quantification of palivizumab was then conducted using Human IgG total Ready-Set-Go! ® kits (Affymetrix/eBioscience Inc., San Diego, CA, USA). No release of palivizumab into the supernatant at acidic pH was observed even after 24 hours. However, at pH 6.5, most of the antibody was released into the supernatant within 1 hour (Fig. 24).
• HUMTRA is a tumor necrosis factor (TNF) blocker indicated for treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and plaque psoriasis.
• Adalimumab is supplied as a sterile, preservative-free solution of adalimumab for subcutaneous administration.
• the drug product is supplied as either a single-use, prefilled pen or as a single-use, 1 mL prefilled glass syringe. Enclosed within the pen is a single-use, 1 mL prefilled glass syringe.
• the solution of adalimumab is clear and colorless, with a pH of about 5.2.
• Each syringe delivers 0.8 mL (40 mg) of drug product.
• Each 0.8 mL of this dosage form contains 40 mg adalimumab, 4.93 mg sodium chloride, 0.69 mg monobasic sodium phosphate dihydrate, 1.22 mg dibasic sodium phosphate dihydrate, 0.24 mg sodium citrate, 1.04 mg citric acid monohydrate, 9.6 mg mannitol, 0.8 mg polysorbate 80, and water for injection USP.
• Sodium hydroxide is added as necessary to adjust pH.
• This dosage form is for intramuscular injection.
• the formulation was diluted to 1 mg/mL with the respective formulation buffer.
• Two mL of adalimumab was added to 20 mg EUDRAGIT L 100 in a 10 mL vial. 1.0 mL samples of this solution were placed in 10 mL vials and lyophilized.
• FaSSGF fibroblast growth factor
• FaSSIF FaSSIF
• 120 ⁇ samples were taken at 0, 1, 2, 4, 8, and 24 hours, placed in 1.5 mL centrifuge tubes and centrifuged at 10,000 rpm for 5 minutes. The supernatant was assayed for its activity against TNF using a functional ELISA assay.
• each sample was diluted 10,000 fold with either FaSSGF or FaSSIF and further diluted 6 fold with dilution sample buffer from the kit Adalimumab (HUMIRA) ELISA Assay Kit (Eagle Biosciences, Inc., Nashua, NH, USA). There was no release of adalimumab into the supernatant in the acidic medium even after 24 hrs. However, at pH 6.5, most of the antibody was released into the supernatant within 1 hour (Fig. 25).
• Citric acid monohydrate 1.3 mM
• ACTEMRA tocilizumab
• IL-6 interleukin-6 receptor antagonist
• Inactive ingredients are L-arginine, L-arginine hydrochloride, Lmethionine, L-histidine, L-histidine hydrochloride monohydrate. This dosage form is for subcutaneous injection.
• the formulation was diluted to 2 mg/mL with the respective formulation buffer.
• tocilizumab was added to 20 mg EUDRAGIT L 100 in a 10 mL vial, and then one ml the pH 6.5 buffer was added. The pH was then adjusted to 6.8. 1.0 mL samples of the solution were placed in 10 mL vials and lyophilized.
• FaSSGF pH 2.1
• FaSSIF FaSSIF
• 120 ⁇ samples were taken at 0, 1, 2, 4, 8, and 24 hours, placed in 1.5 mL centrifuge tubes and centrifuged at 10,000 rpm for 5 minutes.
• the activity of the recovered tocilizumab was evaluated with a functional ELISA assay.
• FaSSGF pH 1.5-2.0
• FaSSIF FaSSIF
• the data indicated that ascorbic acid is released only at pH 6.5 and not significantly released at very acidic pH
• the mean particle size of the final formulation by DLS was 34.9 nm (Fig. 28).
• the results suggest that the formulation is useful for oral delivery of vitamin C, providing a high load of 175 mg/mL.
• the formulation is easily lyophilizable and can be delivered as a powder for suspension, tablet, or capsule, or can be delivered as a stable aqueous suspension for pediatric formulation.
• Example 17 Preparation of Bovine Serum Albumin-Containing Nanoparticles by the Solvent- Based Method.
• insulin is soluble at acidic pH but not at neutral pH.
• 10 mg/mL insulin solution was prepared by first dissolving insulin in 0.01N HC1.
• 0.1 mL of the insulin solution was added to 1 mL of 2% EUDRAGIT L 100 in ethanol, there was no visible precipitation, indicating that at acidic pH insulin is soluble even at 90% of organic solvent.
• the formulation was neutralized with 0.1N NaOH, insulin and EUDRAGIT co- precipitated.
• the precipitate contained nanoparticles with a Z average particle size of about 1110 nm. The samples were kept at -20° C for 30 minutes and then centrifuged at 3200 rpm.
• Insulin-containing nanoparticles were formed by the solvent-free method as follows. A formulation having the following composition was prepared:
• the formulation had a particle size of 18 nm based on DLS analysis. 1 ml aliquots were distributed in 20 mL vials and lyophilized. One vial was reconstituted with FASSGF and the pH was adjusted to pH 1.6. The resulting suspension was cloudy. The second vial was reconstituted with FASSIF and the pH of the reconstituted solution was pH 5.5. The resulting suspension was white opalescent. A third vial was reconstituted with FASSIF and the pH was adjusted to 6.5. The resulting suspension was clear and transparent. The samples were transferred to dialysis tubings with a molecular weight cutoff of 50,000 Da.
• the samples were dialyzed against 2 mL of FASSGF pH 1.6, FASSIF pH 5.5, or FASSIF at pH 6.5 and insulin release from the dialysis tubings was monitored at 0, 0.15, 0.30, 1.0, 2.0, 4.0, and 24 hours by RP-HPLC.
• the HPLC data indicated that insulin remained tightly associated with the nanoparticles at any pH for a period of 24 hrs suggesting.
• the FASSIF pH 6.5 sample was removed from the inside of the dialysis bag and tested for the insulin content by RP-HPLC method. The data indicated that full recovery of 2 mg/mL insulin was seen for the sample inside the dialysis bag.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Biochemistry (AREA)
• Epidemiology (AREA)
• Diabetes (AREA)
• Biomedical Technology (AREA)
• Physics & Mathematics (AREA)
• Nanotechnology (AREA)
• Optics & Photonics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Virology (AREA)
• Endocrinology (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Pulmonology (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Emergency Medicine (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Oncology (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=61830540

Family Applications (1)

Country Status (8)

Cited By (2)

Families Citing this family (2)

Citations (4)

Family Cites Families (47)

• 2016
  • 2016-10-12 US US15/291,480 patent/US11491114B2/en active Active
• 2017
  • 2017-10-12 CA CA3078570A patent/CA3078570A1/en active Pending
  • 2017-10-12 CN CN201780076441.1A patent/CN110049759A/zh active Pending
  • 2017-10-12 WO PCT/US2017/056320 patent/WO2018071655A1/en not_active Ceased
  • 2017-10-12 KR KR1020197013487A patent/KR102580705B1/ko active Active
  • 2017-10-12 EP EP17860772.7A patent/EP3525772A4/en active Pending
  • 2017-10-12 JP JP2019541672A patent/JP7046081B2/ja active Active
  • 2017-10-12 KR KR1020237031642A patent/KR20230135694A/ko active Pending
  • 2017-10-12 AU AU2017341753A patent/AU2017341753B2/en active Active
• 2022
  • 2022-10-03 US US17/958,815 patent/US20230034964A1/en active Pending
• 2024
  • 2024-03-05 AU AU2024201438A patent/AU2024201438A1/en not_active Abandoned

Patent Citations (4)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events